What are the Historical Developments and Current Growth Metrics of the Generic Musculoskeletal Disorders Drugs Market?
The generic musculoskeletal disorders drugs market has seen considerable growth due to a variety of factors.
• The market size for generic drugs for musculoskeletal disorders has been witnessing steady growth over the recent years. The market, proliferating from $0.06 billion in 2024, is predicted to reach $0.06 billion in 2025, registering a compound annual growth rate (CAGR) of 6.7%. The growth during the historical period can be credited to the prevalence of musculoskeletal disorders, regulatory framework, development in healthcare infrastructure, patient awareness and education, and economic factors.
What Does Future Hold for The Generic Musculoskeletal Disorders Drugs Market Size Evolve over the Forecast Period?
The Generic Musculoskeletal Disorders Drugs market is expected to maintain its strong growth trajectory in upcoming years.
• The market size for generic drugs pertaining to musculoskeletal disorders is projected to experience robust expansion in the upcoming years, reaching $0.08 billion by 2029, with a compound annual growth rate (CAGR) of 7.2%.
The growth anticipated during the forecast period is influenced by an increase in population and aging, the emergence of new markets, precision medicine, personalized therapies, healthcare reforms, and global health trends. Key trends expected to be seen throughout this period consist of the incorporation of technology in treatments, initiatives and healthcare policies by the government, a shift towards alternatives for pain management, a surge in the acceptance of biosimilars, and progress in the development of generic drugs.
What Are The Primary Growth Drivers In The Generic Musculoskeletal Disorders Drugs Market?
The considerable incidence of arthritis is anticipated to fuel the expansion of the generic musculoskeletal disorders drugs market. Arthritis, characterized by joint tenderness, swelling, pain, and stiffness, benefits greatly from generic musculoskeletal disorders drugs which alleviate discomfort and stiffness in the muscles and address muscle spasms in patients with arthritis. For example, in March 2022, Versus Arthritis, a charity based in the UK, published data that revealed approximately 10 million people in the UK were diagnosed with osteoarthritis, which included 5.4 million with knee OA, 3.2 million with hip OA, and about 450,000 with rheumatoid arthritis coupled with 190,000 having psoriatic arthritis. This signifies over 20 million individuals coping with musculoskeletal conditions, leading to more than 30 million prescriptions that were dispensed for these conditions costing roughly £139 million in the year 2022-2023. Therefore, the significant incidence of arthritis is acting as a catalyst for the growth of the generic musculoskeletal disorders drugs market.
What Is The Segmentation Of The Global Generic Musculoskeletal Disorders Drugs Market?
The generic musculoskeletal disorders drugs market covered in this report is segmented –
1) By Treatment Type: Medication, Therapy, Surgery, Other Treatment Types
2) By Disorder Type: Osteoarthritis, Rheumatoid Arthritis, Spondylarthritis, Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Fibromyalgia, Other Disorder Types
3) By Route Of Administration: Oral, Parenteral, Other Routes
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Drug Store, Online Pharmacy
Subsegments:
1) By Medication: Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Analgesics, Corticosteroids, Disease-Modifying Antirheumatic Drugs (DMARDs), Biologics
2) By Therapy: Physical Therapy, Occupational Therapy, Chiropractic Treatment, Massage Therapy
3) By Surgery: Joint Replacement Surgery, Arthroscopy, Spinal Surgery, Fusion Surgery
4) By Other Treatment Types: Lifestyle Modifications, Alternative Therapies, Assistive Devices
Pre-Book The Generic Musculoskeletal Disorders Drugs Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Emerging Trends Are Shaping The Generic Musculoskeletal Disorders Drugs Market Landscape?
The increasing trend of strategic collaborations is becoming quite significant in the generic musculoskeletal disorders drugs market. Several firms in this market are entering into partnerships to boost their market standing. For example, in July 2022, Mitsubishi Tanabe Pharma Corporation, originated from Japan, entered into a business tie-up with Eli Lilly and Company, a pharma company based in the US. This collaboration allows the two companies to expand their product offerings and provide patients with effective treatment solutions for conditions like diabetes among other diseases. Furthermore, in February 2022, Pfizer Inc, a US-led pharmaceutical and biotech giant, established a partnership with Alex Therapeutics, a digital therapeutics firm based in Sweden. This innovative strategic partnership provides patients with evidence-supported, clinically validated, and personalized digital therapeutics.
Who Are the Key Players In The Generic Musculoskeletal Disorders Drugs Market?
Major companies operating in the generic musculoskeletal disorders drugs market include:
• Pfizer Inc.
• Sanofi S.A.
• Eli Lilly and Company
• Ampio Pharmaceuticals Inc.
• Amgen Inc.
• Boehringer Ingelheim International GmbH
• Merck & Co. Inc.
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceuticals Industries Ltd.
• AstraZeneca plc
• Mitsubishi Tanabe Pharma Corporation
• Horizon Therapeutics plc
• Eisai Co. Ltd.
• Biogen Inc.
• Sino Biopharmaceutical Limited
• Bristol-Myers Squibb Company
• Johnson & Johnson Services Inc.
• AbbVie Inc.
• Novartis AG
• F. Hoffmann-La Roche Ltd.
• Bayer AG
• Mylan Pharmaceuticals Inc.
• Taisho Pharmaceutical Holdings Co. Ltd.
• Flexion Therapeutics Inc.
What Are The Regional Insights Into The Generic Musculoskeletal Disorders Drugs Market?
Asia-Pacific was the largest region in the generic musculoskeletal disorders drugs market in 2024. The regions covered in the generic musculoskeletal disorders drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
